Chardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23

Benzinga Newsdesk www.benzinga.com Positive 85.8%

Neg 0% Neu 0% Pos 85.8%

Chardan Capital analyst Andreas Argyrides maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $21 to $23.